MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ
48.93
+1.44
+3.03%
After Hours: 48.93 0 0.00% 16:08 12/02 EST
OPEN
46.90
PREV CLOSE
47.49
HIGH
49.04
LOW
46.65
VOLUME
651.51K
TURNOVER
0
52 WEEK HIGH
111.78
52 WEEK LOW
40.78
MARKET CAP
2.93B
P/E (TTM)
-4.0448
1D
5D
1M
3M
1Y
5Y
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 2d ago
Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 3d ago
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Zacks · 11/23 15:51
Blueprint Medicines Submits Supplemental New Drug Application To FDA For AYVAKIT® (avapritinib) For Treatment Of Indolent Systemic Mastocytosis
Benzinga · 11/22 21:39
Ken Fisher Super Stocks: 10 Biggest Small-Cap Stocks
In this article, we discuss the 10 biggest small-cap stocks in the Ken Fisher portfolio. If you want to see more stocks in this selection, check out Ken Fisher Super Stocks: 5 Biggest Small-Cap Stocks. US stocks have been beaten down by inflation recently....
Insider Monkey · 11/17 14:52
Blueprint Medicines Third Quarter 2022 Earnings: Beats Expectations
Blueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2022 Results Key Financial Results Revenue: US$66.0m (up 173% from 3Q...
Simply Wall St. · 11/08 10:28
Blueprint Medicines's Return On Capital Employed Overview
Benzinga · 11/07 14:21
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective November 1, 2022, the Compensation Committee of Blueprint Medicines'...
PR Newswire · 11/04 20:01
More
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.